Human Papillomavirus Infection and Cervical Cytology in Women Screened for Cervical Cancer in the United States, 2003–2005

Abstract

High-risk HPV was widespread among women receiving cervical screening in the United States. Many women 30 years of age or older with normal Pap tests would need follow-up if Hybrid Capture 2 testing is added to cytology screening.

Clinical Experience with the Cervista HPV HR Assay

“…11,14 -16 In all tested groups, an inverse relationship was observed between HR-HPV positivity rate and increasing age, a pattern consistent with findings in numerous studies of HPV prevalence in developed countries. [17][18][19][20] Samples with ASC-US cytological interpretations demonstrated a higher HR-HPV positivity rate in the hc2 population (59.4%) than in the Cervista population (48.5%). Previously reported rates of HR-HPV positivity in samples with ASC-US cytological interpretations vary widely, primarily because of differing HR-HPV prevalence in tested populations; however, in the present study, results in both populations were comparable to the benchmark of 50.7% established by the ASCUS/LSIL Triage Study for Cervical Cancer.…”

“…The hc2 platform uses a signal amplification method in which target HPV DNA from any of the 13 high-risk HPV types tested (HPV 16,18,31,33,35,39,45, 51, 52, 56, 58, 59, and 68) is hybridized with HPV-specific RNA probes. Some cross-reactivity of the probes with other HPV types (including type 66) also occurs.…”

“…Since the identification of HPV as the primary etiologic agent of cervical cancer, 1 14 sexually transmitted oncogenic variants have been identified. These variants, referred to as the high-risk subtypes (HPV 16,18,31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), are responsible for most cervical cancers worldwide. [2][3][4] The remarkable success of Papanicolaou test-based cervical cancer screening programs demonstrates that cervical cancer is largely preventable.…”

Sexually Transmitted Infections: An Overview

“…Therefore, its pathogenesis and epidemiology are not completely understood and require study (Veeranna and Raghu, 2003 (Datta et al, 2008).…”

Evaluation of cervicovaginal smear results at postmenopausal period

“…Subsequently, this classification was revised in 1991 and 2001 [6] . Despite the significant improvement in cervical cancer death rates, there are still conflicting opinions on appropriate cancer screening protocols throughout the life span [7] . Regular Pap smear screening is usually recommended until the age of 65-70.…”